Business Description
Barinthus Biotherapeutics PLC
ISIN : US91864C1071
Share Class Description:
BRNS: ADRDescription
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.38 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.68 | |||||
| Beneish M-Score | -1.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -94.1 | |||||
| 3-Year EBITDA Growth Rate | 81.5 | |||||
| 3-Year EPS without NRI Growth Rate | 83.4 | |||||
| 3-Year FCF Growth Rate | 81.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 5.12 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 16.47 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.05 | |||||
| 9-Day RSI | 46.19 | |||||
| 14-Day RSI | 49.32 | |||||
| 6-1 Month Momentum % | -46.7 | |||||
| 12-1 Month Momentum % | -57.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.93 | |||||
| Quick Ratio | 8.93 | |||||
| Cash Ratio | 7.04 | |||||
| Days Sales Outstanding | 8.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.3 | |||||
| Shareholder Yield % | -5.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -415.08 | |||||
| Net Margin % | -386.31 | |||||
| FCF Margin % | -414.79 | |||||
| ROE % | -33.24 | |||||
| ROA % | -28.36 | |||||
| ROIC % | -95.94 | |||||
| 3-Year ROIIC % | -100.5 | |||||
| ROC (Joel Greenblatt) % | -310.6 | |||||
| ROCE % | -31.07 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.55 | |||||
| PB Ratio | 0.34 | |||||
| Price-to-Tangible-Book | 0.43 | |||||
| EV-to-EBIT | 0.67 | |||||
| EV-to-EBITDA | 0.74 | |||||
| EV-to-Revenue | -2.61 | |||||
| EV-to-Forward-Revenue | 14.21 | |||||
| EV-to-FCF | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 0.51 | |||||
| Price-to-Net-Cash | 0.7 | |||||
| Earnings Yield (Greenblatt) % | 149.25 | |||||
| FCF Yield % | -114.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BRNS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Barinthus Biotherapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.969 | ||
| EPS (TTM) ($) | -1.49 | ||
| Beta | -0.49 | ||
| Volatility % | 67.19 | ||
| 14-Day RSI | 49.32 | ||
| 14-Day ATR ($) | 0.102528 | ||
| 20-Day SMA ($) | 1.369754 | ||
| 12-1 Month Momentum % | -57.84 | ||
| 52-Week Range ($) | 1.11 - 4.1591 | ||
| Shares Outstanding (Mil) | 40.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Barinthus Biotherapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Barinthus Biotherapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Barinthus Biotherapeutics PLC Frequently Asked Questions
What is Barinthus Biotherapeutics PLC(BRNS)'s stock price today?
The current price of BRNS is $1.35. The 52 week high of BRNS is $4.16 and 52 week low is $1.11.
When is next earnings date of Barinthus Biotherapeutics PLC(BRNS)?
The next earnings date of Barinthus Biotherapeutics PLC(BRNS) is 2024-11-08 Est..
Does Barinthus Biotherapeutics PLC(BRNS) pay dividends? If so, how much?
Barinthus Biotherapeutics PLC(BRNS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers